Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2024-10-23 Major Shareholding Noti…
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Franchissement de seuil
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuil (articles L. 233-7 du code de commerce)" and reports that Perceptive Advisors, LLC crossed the 5% ownership threshold of INVENTIVA's capital on October 17, 2024. This type of filing, which reports changes in significant share ownership levels crossing regulatory thresholds (like 5%), directly corresponds to the definition of Major Shareholding Notification. The French regulatory context (AMF) confirms this is a mandatory disclosure regarding shareholding changes. Therefore, the appropriate code is MRQ.
2024-10-23 French
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. It explicitly states that the entity Invus Public Equities, LP. crossed the 5% threshold of capital and voting rights in INVENTIVA on October 17, 2024. This type of filing, which reports changes in significant share ownership levels crossing predefined thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document length is short (1352 chars), but the content is a direct declaration of a threshold crossing, not an announcement of a report publication.
2024-10-23 French
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to a declaration of crossing shareholding thresholds under French commercial code. It explicitly states that BVF Partners, LP crossed below the 15% capital threshold and the 10% capital/voting rights threshold on October 16, 2024, and now holds 9.81% of the capital. This type of filing, reporting changes in significant share ownership by an entity, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a formal regulatory disclosure regarding ownership changes, not a general regulatory announcement (RNS) or a report itself.
2024-10-23 French
Franchissements de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissements de seuils (article L. 233-7 du code de commerce)" and details changes in share ownership thresholds crossed by a concert group (M. Pierre Broqua and the family group of M. Frédéric Cren) concerning the company INVENTIVA. This type of mandatory disclosure regarding changes in significant shareholdings (crossing thresholds) directly corresponds to the definition of Major Shareholding Notification. The French regulatory context (AMF) confirms this is a filing related to ownership changes, fitting the 'MRQ' category best among the provided options, as it specifically deals with crossing ownership thresholds (e.g., 25%, 20%, 15%, 10%, 5%).
2024-10-22 French
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to a declaration of crossing ownership thresholds under French commercial code. It explicitly states that Andera Partners crossed the 5% threshold of capital and voting rights in INVENTIVA on October 17, 2024. This type of filing, reporting changes in significant share ownership by an entity or individual, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and is a direct regulatory disclosure, not an announcement of a larger report.
2024-10-21 French
Inventiva annonce un abstract « late breaker » sur l’essai clinique de Phase 2, LEGEND, combinant lanifibranor et empagliflozine, lors du Liver Meeting™ 2024 organisé par l’AASLD
Regulatory Filings Classification · 95% confidence The document is a press release from Inventiva, a biopharmaceutical company, announcing that an abstract detailing Phase 2 clinical trial results (LEGEND study) for their drug lanifibranor will be presented at the AASLD Liver Meeting 2024. The text focuses on clinical trial data presentation, drug mechanism (lanifibranor, PPAR agonist), and general company pipeline information. This type of announcement, detailing upcoming presentation of clinical data, is characteristic of communications aimed at investors and the scientific community regarding ongoing research and development progress. It is not a full financial report (10-K, IR), a formal earnings release (ER), or a transcript (CT). Since it is a detailed announcement about clinical trial progress and upcoming data presentation, it fits best under Investor Presentation (IP) or potentially Regulatory Filings (RNS) if no other category fits. Given the detailed scientific and clinical focus, 'Investor Presentation' (IP) is the most appropriate classification, as these press releases often accompany or precede investor-facing materials detailing R&D milestones.
2024-10-21 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.